{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:20:04Z","timestamp":1790497204405,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,5]],"date-time":"2020-07-05T00:00:00Z","timestamp":1593907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,5]],"date-time":"2020-07-05T00:00:00Z","timestamp":1593907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s11060-020-03578-6","type":"journal-article","created":{"date-parts":[[2020,7,5]],"date-time":"2020-07-05T13:02:35Z","timestamp":1593954155000},"page":"113-122","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Immune checkpoint inhibition for pediatric patients with recurrent\/refractory CNS tumors: a single institution experience"],"prefix":"10.1007","volume":"149","author":[{"given":"Chantel","family":"Cacciotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungwhan","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanda","family":"Alexandrescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ann","family":"Zimmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabitha M.","family":"Cooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Chordas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Clymer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0713-6384","authenticated-orcid":false,"given":"Kee Kiat","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,5]]},"reference":[{"key":"3578_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252\u2013264. https:\/\/doi.org\/10.1038\/nrc3239","journal-title":"Nat Rev Cancer"},{"key":"3578_CR2","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1002\/cncr.30642","volume":"123","author":"DB Johnson","year":"2017","unstructured":"Johnson DB, Sullivan RJ, Menzies AM (2017) Immune checkpoint inhibitors in challenging populations. Cancer 123:1904\u20131911. https:\/\/doi.org\/10.1002\/cncr.30642","journal-title":"Cancer"},{"key":"3578_CR3","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.canlet.2017.11.014","volume":"414","author":"F Teng","year":"2018","unstructured":"Teng F, Meng X, Kong L, Yu J (2018) Progress and challenges of predictive biomarkers of anti PD-1\/PD-L1 immunotherapy: a systematic review. Cancer Lett 414:166\u2013173. https:\/\/doi.org\/10.1016\/j.canlet.2017.11.014","journal-title":"Cancer Lett"},{"key":"3578_CR4","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.it.2019.05.009","volume":"40","author":"SS Wang","year":"2019","unstructured":"Wang SS, Bandopadhayay P, Jenkins MR (2019) Towards immunotherapy for pediatric brain tumors. Trends Immunol 40:748\u2013761. https:\/\/doi.org\/10.1016\/j.it.2019.05.009","journal-title":"Trends Immunol"},{"key":"3578_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.phrs.2011.09.002","volume":"65","author":"G Graziani","year":"2012","unstructured":"Graziani G, Tentori L, Navarra P (2012) Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacol Res 65:9\u201322. https:\/\/doi.org\/10.1016\/j.phrs.2011.09.002","journal-title":"Pharmacol Res"},{"key":"3578_CR6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s11060-016-2202-1","volume":"129","author":"M Sabel","year":"2016","unstructured":"Sabel M, Fleischhack G, Tippelt S, Gustafsson G, Doz F, Kortmann R, Massimino M, Navajas A, von Hoff K, Rutkowski S, Warmuth-Metz M, Clifford SC, Pietsch T, Pizer B, Lannering B, Group S-EBT (2016) Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study. J Neurooncol 129:515\u2013524. https:\/\/doi.org\/10.1007\/s11060-016-2202-1","journal-title":"J Neurooncol"},{"key":"3578_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11060-017-2701-8","volume":"137","author":"C Kline","year":"2018","unstructured":"Kline C, Felton E, Allen IE, Tahir P, Mueller S (2018) Survival outcomes in pediatric recurrent high-grade glioma: results of a 20-year systematic review and meta-analysis. J Neurooncol 137:103\u2013110. https:\/\/doi.org\/10.1007\/s11060-017-2701-8","journal-title":"J Neurooncol"},{"key":"3578_CR8","doi-asserted-by":"publisher","first-page":"91779","DOI":"10.18632\/oncotarget.21586","volume":"8","author":"AC Filley","year":"2017","unstructured":"Filley AC, Henriquez M, Dey M (2017) Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget 8:91779\u201391794. https:\/\/doi.org\/10.18632\/oncotarget.21586","journal-title":"Oncotarget"},{"key":"3578_CR9","unstructured":"Bristol-Myers Squibb provides update on phase 3 Opdivo (nivolumab) checkmate -548 trial in patients with newly diagnosed MGMT-methylated glioblastoma multiforme. Bristol-Myers Squibb Company, Princeton, NJ. https:\/\/bit.ly\/2ktBxYb. Accessed 5 Sept 2019"},{"key":"3578_CR10","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","volume":"25","author":"TF Cloughesy","year":"2019","unstructured":"Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, O\u2019Brien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins RM (2019) Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med 25:477\u2013486. https:\/\/doi.org\/10.1038\/s41591-018-0337-7","journal-title":"Nat Med"},{"key":"3578_CR11","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1158\/1078-0432.CCR-15-0491","volume":"22","author":"MS Merchant","year":"2016","unstructured":"Merchant MS, Wright M, Baird K, Wexler LH, Rodriguez-Galindo C, Bernstein D, Delbrook C, Lodish M, Bishop R, Wolchok JD, Streicher H, Mackall CL (2016) Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors. Clin Cancer Res 22:1364\u20131370. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0491","journal-title":"Clin Cancer Res"},{"key":"3578_CR12","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1097\/MPH.0000000000001339","volume":"41","author":"HS Gorsi","year":"2019","unstructured":"Gorsi HS, Malicki DM, Barsan V, Tumblin M, Yeh-Nayre L, Milburn M, Elster JD, Crawford JR (2019) Nivolumab in the treatment of recurrent or refractory pediatric brain tumors: a single institutional experience. J Pediatr Hematol Oncol 41:e235\u2013e241. https:\/\/doi.org\/10.1097\/MPH.0000000000001339","journal-title":"J Pediatr Hematol Oncol"},{"key":"3578_CR13","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s11060-016-2190-1","volume":"129","author":"DT Blumenthal","year":"2016","unstructured":"Blumenthal DT, Yalon M, Vainer GW, Lossos A, Yust S, Tzach L, Cagnano E, Limon D, Bokstein F (2016) Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. J Neurooncol 129:453\u2013460. https:\/\/doi.org\/10.1007\/s11060-016-2190-1","journal-title":"J Neurooncol"},{"issue":"Suppl 2","key":"3578_CR14","doi-asserted-by":"publisher","first-page":"i100","DOI":"10.1093\/neuonc\/noy059.325","volume":"20","author":"E Hwang","year":"2018","unstructured":"Hwang E, Onar A, Young-Poussaint T, Mitchell D, Kilburn L, Margol A, Gilheeny S, Lin T, Dunkel I, Fouladi M (2018) IMMU-09, Outcome of patients with recurrent diffuse intrinsic pontine glioma (DIPG) treated with pembrolizumab (ANTI-PD-1): a pediatric brain tumor consortium study (PBTC045). Neuro-Oncology 20(Suppl 2):i100. https:\/\/doi.org\/10.1093\/neuonc\/noy059.325","journal-title":"Neuro-Oncology"},{"key":"3578_CR15","doi-asserted-by":"publisher","first-page":"751","DOI":"10.5858\/arpa.2016-0527-OA","volume":"141","author":"EP Garcia","year":"2017","unstructured":"Garcia EP, Minkovsky A, Jia Y, Ducar MD, Shivdasani P, Gong X, Ligon AH, Sholl LM, Kuo FC, MacConaill LE, Lindeman NI, Dong F (2017) Validation of OncoPanel: a targeted next-generation sequencing assay for the detection of somatic variants in cancer. Arch Pathol Lab Med 141:751\u2013758. https:\/\/doi.org\/10.5858\/arpa.2016-0527-OA","journal-title":"Arch Pathol Lab Med"},{"key":"3578_CR16","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","volume":"16","author":"H Okada","year":"2015","unstructured":"Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson JH, Wen PY, Reardon DA (2015) Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 16:e534\u2013e542. https:\/\/doi.org\/10.1016\/S1470-2045(15)00088-1","journal-title":"Lancet Oncol"},{"key":"3578_CR17","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1200\/JCO.2004.11.053","volume":"22","author":"S Modak","year":"2004","unstructured":"Modak S, Gardner S, Dunkel IJ, Balmaceda C, Rosenblum MK, Miller DC, Halpern S, Finlay JL (2004) Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors. J Clin Oncol 22:1934\u20131943. https:\/\/doi.org\/10.1200\/JCO.2004.11.053","journal-title":"J Clin Oncol"},{"key":"3578_CR18","doi-asserted-by":"publisher","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","volume":"2","author":"A Haslam","year":"2019","unstructured":"Haslam A, Prasad V (2019) Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open 2:e192535. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.2535","journal-title":"JAMA Netw Open"},{"key":"3578_CR19","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006\u20132017. https:\/\/doi.org\/10.1056\/NEJMoa1414428","journal-title":"N Engl J Med"},{"key":"3578_CR20","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A, Investigators K (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521\u20132532. https:\/\/doi.org\/10.1056\/NEJMoa1503093","journal-title":"N Engl J Med"},{"key":"3578_CR21","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375\u2013384. https:\/\/doi.org\/10.1016\/S1470-2045(15)70076-8","journal-title":"Lancet Oncol"},{"key":"3578_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain L, Diem S, Larkin J (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44:51\u201360. https:\/\/doi.org\/10.1016\/j.ctrv.2016.02.001","journal-title":"Cancer Treat Rev"},{"key":"3578_CR23","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","volume":"16","author":"AM Eggermont","year":"2015","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebb\u00e9 C, Ferraresi V, Smylie M, Weber JS, Maio M, Konto C, Hoos A, de Pril V, Gurunath RK, de Schaetzen G, Suciu S, Testori A (2015) Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16:522\u2013530. https:\/\/doi.org\/10.1016\/S1470-2045(15)70122-1","journal-title":"Lancet Oncol"},{"key":"3578_CR24","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M, Larkin JMG, Lorigan P, Neyns B, Blank CU, Petrella TM, Hamid O, Su SC, Krepler C, Ibrahim N, Long GV (2019) Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol 20:1239\u20131251. https:\/\/doi.org\/10.1016\/S1470-2045(19)30388-2","journal-title":"Lancet Oncol"},{"key":"3578_CR25","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1056\/NEJMc1509660","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:1270\u20131271. https:\/\/doi.org\/10.1056\/NEJMc1509660","journal-title":"N Engl J Med"},{"key":"3578_CR26","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Ar\u00e9n Frontera O, Melichar B, Choueiri TK, Plimack ER, Barth\u00e9l\u00e9my P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B, Investigators C (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378:1277\u20131290. https:\/\/doi.org\/10.1056\/NEJMoa1712126","journal-title":"N Engl J Med"},{"key":"3578_CR27","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S1470-2045(20)30023-1","volume":"21","author":"KL Davis","year":"2020","unstructured":"Davis KL, Fox E, Merchant MS, Reid JM, Kudgus RA, Liu X, Minard CG, Voss S, Berg SL, Weigel BJ, Mackall CL (2020) Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol 21:541\u2013550. https:\/\/doi.org\/10.1016\/S1470-2045(20)30023-1","journal-title":"Lancet Oncol"},{"key":"3578_CR28","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","volume":"22","author":"M Freeman-Keller","year":"2016","unstructured":"Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS (2016) Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22:886\u2013894. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1136","journal-title":"Clin Cancer Res"},{"key":"3578_CR29","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, Nakagawa K (2018) Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 4:374\u2013378. https:\/\/doi.org\/10.1001\/jamaoncol.2017.2925","journal-title":"JAMA Oncol"},{"key":"3578_CR30","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s40425-019-0779-6","volume":"7","author":"P Xing","year":"2019","unstructured":"Xing P, Zhang F, Wang G, Xu Y, Li C, Wang S, Guo Y, Cai S, Wang Y, Li J (2019) Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO\u2009+\u2009IPI: a systematic review and meta-analysis. J Immunother Cancer 7:341. https:\/\/doi.org\/10.1186\/s40425-019-0779-6","journal-title":"J Immunother Cancer"},{"key":"3578_CR31","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pag\u00e8s C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohou\u00e9 F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pag\u00e8s F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960\u20131964. https:\/\/doi.org\/10.1126\/science.1129139","journal-title":"Science"},{"key":"3578_CR32","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pag\u00e8s F, Saut\u00e8s-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12:298\u2013306. https:\/\/doi.org\/10.1038\/nrc3245","journal-title":"Nat Rev Cancer"},{"key":"3578_CR33","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","volume":"391","author":"F Pag\u00e8s","year":"2018","unstructured":"Pag\u00e8s F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-B\u00f6rger E, Hartmann A, Geppert C, Kolwelter J, Merkel S, Gr\u00fctzmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, L\u00e9onard D, Remue C, Wang JY, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson EK, Zavadova E, Vocka M, Spacek J, Petruzelka L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Fredriksen T, Buttard B, Angelova M, Vasaturo A, Maby P, Church SE, Angell HK, Lafontaine L, Bruni D, El Sissy C, Haicheur N, Kirilovsky A, Berger A, Lagorce C, Meyers JP, Paustian C, Feng Z, Ballesteros-Merino C, Dijkstra J, van de Water C, van Lent-van Vliet S, Knijn N, Mu\u0219in\u0103 AM, Scripcariu DV, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Torigoe T, Sato N, Furuhata T, Takemasa I, Itoh K, Patel PS, Vora HH, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Wang Y, Zhang G, Kawakami Y, Marincola FM, Ascierto PA, Sargent DJ, Fox BA, Galon J (2018) International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 391:2128\u20132139. https:\/\/doi.org\/10.1016\/S0140-6736(18)30789-X","journal-title":"Lancet"},{"key":"3578_CR34","doi-asserted-by":"publisher","first-page":"e0194594","DOI":"10.1371\/journal.pone.0194594","volume":"13","author":"B Liu","year":"2018","unstructured":"Liu B, Arakawa Y, Yokogawa R, Tokunaga S, Terada Y, Murata D, Matsui Y, Fujimoto KI, Fukui N, Tanji M, Mineharu Y, Minamiguchi S, Miyamoto S (2018) PD-1\/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3\u2009+\u2009and CD8\u2009+\u2009infiltrating lymphocytes. PLoS ONE 13:e0194594. https:\/\/doi.org\/10.1371\/journal.pone.0194594","journal-title":"PLoS ONE"},{"key":"3578_CR35","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1093\/jnen\/nly008","volume":"77","author":"ME Wildeman","year":"2018","unstructured":"Wildeman ME, Shepard MJ, Oldfield EH, Lopes MBS (2018) Central nervous system germinomas express programmed death ligand 1. J Neuropathol Exp Neurol 77:312\u2013316. https:\/\/doi.org\/10.1093\/jnen\/nly008","journal-title":"J Neuropathol Exp Neurol"},{"key":"3578_CR36","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.4049\/jimmunol.0803424","volume":"182","author":"SN Willis","year":"2009","unstructured":"Willis SN, Mallozzi SS, Rodig SJ, Cronk KM, McArdel SL, Caron T, Pinkus GS, Lovato L, Shampain KL, Anderson DE, Anderson RC, Bruce JN, O\u2019Connor KC (2009) The microenvironment of germ cell tumors harbors a prominent antigen-driven humoral response. J Immunol 182:3310\u20133317. https:\/\/doi.org\/10.4049\/jimmunol.0803424","journal-title":"J Immunol"},{"key":"3578_CR37","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","volume":"27","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L (2016) Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol 27:1482\u20131492. https:\/\/doi.org\/10.1093\/annonc\/mdw168","journal-title":"Ann Oncol"},{"key":"3578_CR38","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/neuonc\/noz126.282","volume":"21","author":"AK Chan","year":"2019","unstructured":"Chan AK, Shi ZF, Lo KW, Ng HK, Lau CC (2019) P14.47 Tissue immune markers for central nervous system germinoma. Neuro-Oncology 21:377\u2013378. https:\/\/doi.org\/10.1093\/neuonc\/noz126.282","journal-title":"Neuro-Oncology"},{"key":"3578_CR39","doi-asserted-by":"publisher","first-page":"e1542245","DOI":"10.1080\/2162402X.2018.1542245","volume":"8","author":"R Boldrini","year":"2019","unstructured":"Boldrini R, De Pasquale MD, Melaiu O, Chierici M, Jurman G, Benedetti MC, Salfi NC, Castellano A, Collini P, Furlanello C, Pistoia V, Cifaldi L, Terenziani M, Fruci D (2019) Tumor-infiltrating T cells and PD-L1 expression in childhood malignant extracranial germ-cell tumors. Oncoimmunology 8:e1542245. https:\/\/doi.org\/10.1080\/2162402X.2018.1542245","journal-title":"Oncoimmunology"},{"key":"3578_CR40","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2017.76.8770","volume":"36","author":"CE Steuer","year":"2018","unstructured":"Steuer CE, Ramalingam SS (2018) Tumor mutation burden: leading immunotherapy to the era of precision medicine? J Clin Oncol 36:631\u2013632. https:\/\/doi.org\/10.1200\/JCO.2017.76.8770","journal-title":"J Clin Oncol"},{"key":"3578_CR41","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12935-019-0929-4","volume":"19","author":"F Galuppini","year":"2019","unstructured":"Galuppini F, Dal Pozzo CA, Deckert J, Loupakis F, Fassan M, Baffa R (2019) Tumor mutation burden: from comprehensive mutational screening to the clinic. Cancer Cell Int 19:209. https:\/\/doi.org\/10.1186\/s12935-019-0929-4","journal-title":"Cancer Cell Int"},{"key":"3578_CR42","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1016\/j.ejca.2013.02.015","volume":"49","author":"RA Droeser","year":"2013","unstructured":"Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, Zlobec I, Eppenberger-Castori S, Tzankov A, Rosso R, Zuber M, Muraro MG, Amicarella F, Cremonesi E, Heberer M, Iezzi G, Lugli A, Terracciano L, Sconocchia G, Oertli D, Spagnoli GC, Tornillo L (2013) Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 49:2233\u20132242. https:\/\/doi.org\/10.1016\/j.ejca.2013.02.015","journal-title":"Eur J Cancer"},{"key":"3578_CR43","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1158\/1078-0432.CCR-13-2702","volume":"20","author":"KA Schalper","year":"2014","unstructured":"Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, Rimm DL (2014) In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res 20:2773\u20132782. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2702","journal-title":"Clin Cancer Res"},{"key":"3578_CR44","doi-asserted-by":"publisher","first-page":"157","DOI":"10.20892\/j.issn.2095-3941.2016.0009","volume":"13","author":"M Mino-Kenudson","year":"2016","unstructured":"Mino-Kenudson M (2016) Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and\/or prognostic in non-small cell lung cancer? Cancer Biol Med 13:157\u2013170. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2016.0009","journal-title":"Cancer Biol Med"},{"key":"3578_CR45","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11060-018-2886-5","volume":"139","author":"K Hwang","year":"2018","unstructured":"Hwang K, Koh EJ, Choi EJ, Kang TH, Han JH, Choe G, Park SH, Yearley JH, Annamalai L, Blumenschein W, Sathe M, McClanahan T, Jung H, Wang KC, Kim SK, Kim CY (2018) PD-1\/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population. J Neurooncol 139:281\u2013291. https:\/\/doi.org\/10.1007\/s11060-018-2886-5","journal-title":"J Neurooncol"},{"key":"3578_CR46","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1126\/science.aad4140","volume":"350","author":"MM Gubin","year":"2015","unstructured":"Gubin MM, Schreiber RD (2015) CANCER. The odds of immunotherapy success. Science 350:158\u2013159. https:\/\/doi.org\/10.1126\/science.aad4140","journal-title":"Science"},{"key":"3578_CR47","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1200\/JCO.2016.66.6552","volume":"34","author":"E Bouffet","year":"2016","unstructured":"Bouffet E, Larouche V, Campbell BB, Merico D, de Borja R, Aronson M, Durno C, Krueger J, Cabric V, Ramaswamy V, Zhukova N, Mason G, Farah R, Afzal S, Yalon M, Rechavi G, Magimairajan V, Walsh MF, Constantini S, Dvir R, Elhasid R, Reddy A, Osborn M, Sullivan M, Hansford J, Dodgshun A, Klauber-Demore N, Peterson L, Patel S, Lindhorst S, Atkinson J, Cohen Z, Laframboise R, Dirks P, Taylor M, Malkin D, Albrecht S, Dudley RW, Jabado N, Hawkins CE, Shlien A, Tabori U (2016) Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 34:2206\u20132211. https:\/\/doi.org\/10.1200\/JCO.2016.66.6552","journal-title":"J Clin Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-020-03578-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-020-03578-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-020-03578-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T23:32:51Z","timestamp":1625441571000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-020-03578-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,5]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["3578"],"URL":"https:\/\/doi.org\/10.1007\/s11060-020-03578-6","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,5]]},"assertion":[{"value":"15 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No conflicts of interests or competing interests to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}